Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products; Draft Guidance for Industry; Availability
🏛 Food and Drug Administration (FDA)FDA-2026-D-2839
Documents
2
Total comments
76
28 awaiting analysis
Comment status
Open
Last activity
Aug 1, 2026
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
📄 Primary document
OtherJun 1, 2026
Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products;
Guidance for Industry - Draft GuidanceClosed on Aug 1, 2026💬 76 comments · 28 awaiting analysis